Publications
26
Citations
105
Est. group size
~16
Recurring co-author estimate
Active years
8
Publishing since 2019
Typically publishes in teams of ~9 · 0% small-team papers (≤3 authors) · across 15 venues
- Abstract 247: Multiomic and preclinical assessment of ATR and Aurora kinase inhibitors in diverse TNBC models.
Cancer Research · 2026
- Abstract 491: Molecular correlates of drug response to identify novel therapeutic combinations in triple-negative breast cancer
Cancer Research · 2025
- Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response
European Urology · 2024
- Abstract A009: Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response
Clinical Cancer Research · 2024
- Abstract 4548: Discovering novel ALK-lung carcinoma therapeutic strategies by identifying combinations with Alectinib from ALK-positive lung carcinoma cell lines
Cancer Research · 2024
- Abstract PO2-16-01: Molecular correlates of drug response to guide therapy in triple-negative breast cancer
Cancer Research · 2024
- Selective and Potent PROTAC Degraders of c-Src Kinase
ACS Chemical Biology · 2023
- Selective and potent PROTAC degraders of c-Src kinase
ChemRxiv · 2023
- 136P Molecular correlates of drug response to guide therapy in TNBC
ESMO Open · 2023
- Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”
Angewandte Chemie International Edition · 2022
- Abstract 3072: Functional assays of drug sensitivity in real-time from patient material for precision oncology in bladder cancer
Cancer Research · 2022
- Reply to Correspondence on “Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase”
Angewandte Chemie · 2022
- Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase
Angewandte Chemie International Edition · 2021
- Synergy and Antagonism between Allosteric and Active‐Site Inhibitors of Abl Tyrosine Kinase
Angewandte Chemie · 2021
- Insights into the modular design of kinase inhibitors and application to Abl and Axl
RSC Medicinal Chemistry · 2021
- Cancer Research×9
- Angewandte Chemie International Edition×2
- Angewandte Chemie×2
- Clinical Cancer Research×2
- European Urology×1
- Ajjai Alva
Medicine · University of Michigan
- Alon Z. Weizer
Medicine · University of Michigan
- Ahmad Shabsigh
Medicine · The Ohio State University
- Ahsan Masood Khan
Medicine · University of Michigan
- Amir Mortazavi
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile